Hepatitis C virus (HCV) infection in humans is almost invariably associated with viral persistence, which leads to the development of hepatocellular carcinoma and autoimmune disease. In chronic HCV patients, cellular immune responses including the production of IL-12 and IFN-g are severely impaired. In addition, HCV-induced immune suppression is associated with increased susceptibility to bacteria and other enteric viral infections. Thus, HCV most likely evolved a strategy to avoid host immune surveillance by encoding gene products, which are capable of dampening host immune responses. To understand the mechanism(s) of immune evasion by HCV and to design strategies for therapeutics and improved immunization, we identified the HCV core protein as an immunomodulatory molecule to inhibit IL- 12 production. In addition, we successfully demonstrated a novel interaction between HCV core and complement receptor (gClqR). Clq is a ligand for gClqR and plays a critical role in innate immunity, as well as, regulation of adaptive immunity. Intriguingly, the binding of extracellular core protein to gClqR on macrophages induced SHP-1 recruitment and SOCS1 mRNA expression. Both SHP-1 and SOCS1 play a role in suppressing intracellular signaling for inflammatory cytokine production. Based on these findings, we hypothesize that the binding of soluble core protein to the gClqR on macrophages leads to SHP-1 and/or SOCSl-dependent suppression of IL-12 production. In this proposal, we will first determine protein(s) recruited to HCV core/gC1qR complex for inhibition of IL- 12 production. Second, we will characterize the role of SHP-1 and SOCS1 in inhibition of IL-12 production by HCV core/gClqR engagement. Third, we will analyze the mechanism responsible for inhibition of IL-12 production by HCV core/gC1qR engagement. The studies proposed here will help to elucidate the mechanisms of HCV core-induced immunosuppression. In addition, they will provide a basis for the rational design of novel therapeutic agents to block the action of HCV-induced immunosuppression.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI057591-01A1
Application #
6872563
Study Section
Special Emphasis Panel (ZRG1-IHD (01))
Program Officer
Koshy, Rajen
Project Start
2004-12-01
Project End
2009-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
1
Fiscal Year
2005
Total Cost
$303,101
Indirect Cost
Name
University of Virginia
Department
Pathology
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Goh, Celeste C; Roggerson, Krystal M; Lee, Hai-Chon et al. (2016) Hepatitis C Virus-Induced Myeloid-Derived Suppressor Cells Suppress NK Cell IFN-? Production by Altering Cellular Metabolism via Arginase-1. J Immunol 196:2283-92
Tacke, Robert S; Tosello-Trampont, Annie; Nguyen, Virginia et al. (2011) Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. J Biol Chem 286:10847-55
Hall, Caroline H T; Kassel, Rachel; Tacke, Robert S et al. (2010) HCV+ hepatocytes induce human regulatory CD4+ T cells through the production of TGF-beta. PLoS One 5:e12154
Cummings, Kara L; Rosen, Hugo R; Hahn, Young S (2009) Frequency of gC1qR+CD4+ T cells increases during acute hepatitis C virus infection and remains elevated in patients with chronic infection. Clin Immunol 132:401-11
Waggoner, Stephen N; Hall, Caroline H T; Hahn, Young S (2007) HCV core protein interaction with gC1q receptor inhibits Th1 differentiation of CD4+ T cells via suppression of dendritic cell IL-12 production. J Leukoc Biol 82:1407-19
Waggoner, Stephen N; Cruise, Michael W; Kassel, Rachel et al. (2005) gC1q receptor ligation selectively down-regulates human IL-12 production through activation of the phosphoinositide 3-kinase pathway. J Immunol 175:4706-14
Joo, Myungsoo; Hahn, Young S; Kwon, Minjae et al. (2005) Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J Virol 79:7648-57